Treatment response, survival, safety, and predictive factors to chimeric antigen receptor T cell therapy in Chinese relapsed or refractory B cell acute lymphoblast leukemia patients | Cell Death & Disease
How to Deal with Regulations to Get Approval for CAR-T Cells
Explaining the hype: CAR T cells | Signals Blog
CAR T-cell therapy
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia | NEJM
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia | NEJM
Clinical development of CAR T cell therapy in China: 2020 update | Cellular & Molecular Immunology
Successful CD19 CAR T Cell Therapy Requires Prior Lymphodepletion Mice... | Download Scientific Diagram
Treatment response, survival, safety, and predictive factors to chimeric antigen receptor T cell therapy in Chinese relapsed or refractory B cell acute lymphoblast leukemia patients | Cell Death & Disease
The Potential Impact of CAR T-Cell Treatment Delays on Society
Dose-dependent thresholds of dexamethasone destabilize CAR T-cell treatment efficacy | PLOS Computational Biology
Are CAR-T therapies living up to their hype? A study using real-world data in two cohorts to determine how well they are actually working in practice compared with bone marrow transplants
Frontiers | Efficacy and Safety of CAR-Modified T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Prospective Clinical Trials
Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy | NEJM
Treatment response, survival, safety, and predictive factors to chimeric antigen receptor T cell therapy in Chinese relapsed or refractory B cell acute lymphoblast leukemia patients | Cell Death & Disease
CAR T-Cell Therapy: Procedure, Prognosis & Side Effects
CAR T Cells: Engineering Immune Cells to Treat Cancer - NCI
If at first you don't succeed: Testing outcomes of second CAR T-cell infusions
5 Developments Changing the CAR-T Landscape
CAR T-cell therapy for cancer and HIV through novel approaches to HIV-associated haematological malignancies - The Lancet Haematology
Clinical development of CAR T cell therapy in China: 2020 update | Cellular & Molecular Immunology
CAR T cell immunotherapy for human cancer | Science
LUDAOPEI HOSPITAL
Success rate of a CAR T-cell therapy
Frontiers | Engineered T Cell Therapy for Cancer in the Clinic
CAR-T with synthetic binder shows 'very promising' results in advanced multiple myeloma
Manufacturing success rate holds back sales of Bristol Myers' CD19 CAR-T cell therapy
